Try our beta test site

Regulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2012 by Postgraduate Institute of Medical Education and Research.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Sanjay K. Bhadada, Postgraduate Institute of Medical Education and Research Identifier:
First received: October 26, 2010
Last updated: July 19, 2012
Last verified: July 2012
The present study is designed to examine the expression of VDR, CaSR, PTH, Cyclin D1, Ki67 and PCNA and to find out its relationship with clinical parameters in parathyroid adenomas. Examination of the contribution of genes expression can elucidate the critical link between proliferation and functional abnormalities in parathyroid adenomas. Alternative to DNA and RNA, protein expression can provide a better understanding of this disease.

Primary Hyperparathyroidism (PHPT)

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Transcriptional and Translational Regulation of Vitamin D Receptor (VDR) and Calcium Sensing Receptor (CaSR) in Patients With Sporadic Primary Hyperparathyroidism

Resource links provided by NLM:

Further study details as provided by Postgraduate Institute of Medical Education and Research:

Biospecimen Retention:   Samples With DNA
Parathyroid Adenoma and normal parathyroid gland

Estimated Enrollment: 50
Study Start Date: October 2007
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Group A
~ 20 sporadic PHPT patients
Group B
~10 normocalcemic euthyroid patients (control tissue)

  Show Detailed Description


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with Primery Hyperparathyroidism (PHPT)

Inclusion Criteria:

  • Patients with surgically verified sporadic PHPT

Exclusion Criteria:

  • Patients with hyperplasia, renal failure and multiple endocrine neoplasia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01228786

Chandigarh, UT, India, 1600012
Sponsors and Collaborators
Postgraduate Institute of Medical Education and Research
Principal Investigator: Dr Sanjay K. Bhadada, DM Indian Counsil of Medical Research
  More Information

Responsible Party: Sanjay K. Bhadada, Associate Professor, Postgraduate Institute of Medical Education and Research Identifier: NCT01228786     History of Changes
Other Study ID Numbers: BHADADA-PGI  BHADADA-SK 
Study First Received: October 26, 2010
Last Updated: July 19, 2012

Keywords provided by Postgraduate Institute of Medical Education and Research:
VDR, CaSR, PTH, Cyclin D1, Ki67, PCNA

Additional relevant MeSH terms:
Hyperparathyroidism, Primary
Parathyroid Diseases
Endocrine System Diseases
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on February 20, 2017